NSE GLAXO · BSE 500660 · Biotechnology & Drugs · NIFTY 500

GlaxoSmithKline Pharmaceuticals Share Price

Market closed · NSE price as of Tue 29 Sep
₹2,783.80 ▼ −₹112.67 · 3.89%
Day range · 28 Sep
₹2,788.80Low₹2,986.65High
52-week range
₹2,088.00Low · 12 Jun 2026₹3,121.10High · 28 Aug 2026

GlaxoSmithKline Pharmaceuticals Overview

Where the price stands, how it has moved and how it sits against its averages.

GlaxoSmithKline Pharmaceuticals shares last traded at ₹2,783.80 on the NSE, down 3.89% on the day. That is 10.8% below the 52-week high of ₹3,121.10 and 33.3% above the 52-week low of ₹2,088.00. The stock trades at 44.12× earnings, above the sector average of 33.72. Its market value is ₹47,126 Cr.

NSE closing prices — daily for the last year, weekly before that — ending at the latest price (Tue 29 Sep). Hover, tap or use the arrow keys to read a day.

Price returns

1 Day▼ −3.89%
1 Week▼ −3.12%
This month▼ −8.73%
3 Months▲ +18.24%
6 Months▲ +23.20%
This year▲ +12.54%
1 Year▲ +4.23%

Share price growth a year (CAGR): 3 years ▲ +21.7% · 5 years ▲ +13.2% · 10 years ▲ +7.1%

Against the market: 1 Month ▼ −5.23% · 3 Months ▲ +24.76% · 6 Months ▲ +24.09% · This year ▲ +31.28% · 1 Year ▲ +12.94%

Shading grows with the size of the move. We ask our data provider for a newer price every 15 minutes while the market is open (9:15 AM–3:30 PM IST); next check from Fri 16 Oct, 9:15 AM. Its quotes are not real-time — the time at the top shows how current the price is.

Moving averages — price is above 3 of 6

  1. 20-day average₹2,900.79 ▼ price 4.0% below
  2. 5-day average₹2,851.66 ▼ price 2.4% below
  3. 10-day average₹2,840.05 ▼ price 2.0% below
  4. Today's price₹2,783.80
  5. 50-day average₹2,776.99 ▲ price 0.2% above
  6. 100-day average₹2,555.66 ▲ price 8.9% above
  7. 300-day average₹2,506.38 ▲ price 11.1% above

Each average is the mean closing price over that many trading days; averages above the current price sit higher on the ladder.

GlaxoSmithKline Pharmaceuticals Financial Results

Revenue and net profit in ₹ crore, with the full statements underneath.

Revenue₹ crore
3,822
Net profit₹ crore · losses below zero
1,695
1,036

Year by year

Fiscal yearRevenueGrowthNet profitNet marginEPSDividend
FY 2026 ₹3,822 Cr ▲ +1.9% ₹1,036 Cr 27.1% ₹61.15 ₹57.00
FY 2025 ₹3,749 Cr ▲ +8.6% ₹928 Cr 24.7% ₹54.76 ₹42.00
FY 2024 ₹3,454 Cr ▲ +6.2% ₹590 Cr 17.1% ₹34.83 ₹32.00
FY 2023 ₹3,252 Cr ▼ −0.8% ₹611 Cr 18.8% ₹35.87 ₹32.00
FY 2022 ₹3,278 Cr ▲ +12.0% ₹1,695 Cr 51.7% ₹22.48 ₹30.00
FY 2021 ₹2,926 Cr ▼ −9.3% ₹358 Cr 12.2% ₹16.96 ₹30.00
FY 2020 ₹3,224 Cr — ₹93 Cr 2.9% ₹6.50 ₹20.00

Balance sheet — FY26

Owes (liabilities)Shareholders' equity
48%
52%
  • Total assets₹4,324 Cr
  • Total liabilities₹2,056 Cr
  • Shareholders' equity₹2,267 Cr
  • Total debt₹33 Cr
  • Cash & investments₹2,755 Cr
  • Current ratio2.03×
  • Revenue growth, 5 yr5.49% a year
  • EPS growth, 5 yr29.24% a year
  • Operating margin (TTM)32.53%
  • Net margin (TTM)27.01%

Cash flow — FY26

Operating activities
▲ ₹903 Cr
Investing activities
▲ ₹397 Cr
Financing activities
▼ −₹737 Cr
Free cash flow
▲ ₹848 Cr
Net change in cash
▲ ₹563 Cr

Right of the line = cash coming in, left = cash going out. Free cash flow = cash from operations minus capital spending.

Full financial statements, FY20–FY26
₹ croreFY20FY21FY22FY23FY24FY25FY26
Total revenue3,224.382,925.603,278.033,251.723,453.713,749.213,821.67
Cost of revenue1,434.731,368.001,482.141,394.281,457.101,512.301,458.32
Gross profit1,789.651,557.611,795.891,857.441,996.612,236.912,363.35
Operating expenses3,525.742,580.442,599.032,513.912,778.002,634.862,574.10
Operating income−301.36345.16679.00737.81675.711,114.351,247.57
Depreciation82.5378.4668.0465.6269.5466.6666.34
Profit before tax305.75453.99779.05836.40816.191,259.881,406.01
Tax195.63166.72398.28228.76226.23332.30370.03
Net profit93.20358.151,694.72610.69589.96927.581,035.98
EPS (₹)6.5016.9622.4835.8734.8354.7661.15
Dividend per share (₹)20.0030.0030.0032.0032.0042.0057.00

GlaxoSmithKline Pharmaceuticals vs Peers

Side by side with other biotechnology & drugs companies. The small bars compare each column.

CompanyPriceChangeMarket capP/EP/BROE (5 yr)Net marginDiv. yield
GlaxoSmithKline Pharmaceuticals This stock ₹2,783.80 ▼ −3.89% ₹47,126 Cr 44.12 20.80 35.40% 27.01% 2.05%
Sun Pharmaceutical Industries ₹1,840.00 ▼ −0.73% ₹4,41,467 Cr 38.40 5.55 14.22% 19.12% 0.83%
Divi's Laboratories ₹9,531.50 ▼ −0.82% ₹2,53,031 Cr 73.32 11.48 16.87% 24.32% 0.41%
Torrent Pharmaceuticals ₹4,869.40 ▼ −2.32% ₹1,85,210 Cr 72.73 19.22 23.00% 15.29% 0.80%
Cipla ₹1,388.90 ▼ −0.59% ₹1,12,203 Cr 27.57 3.33 14.47% 13.74% 0.92%
Zydus Lifesciences ₹1,212.00 ▲ +0.83% ₹1,20,897 Cr 21.19 4.24 17.90% 18.51% 0.09%

Peer prices and ratios as last reported by the data provider. Company names link to their own pages.

Shareholding Pattern

Who owns GlaxoSmithKline Pharmaceuticals shares, quarter by quarter (latest on top).

PromoterFIIMFOther
Jun '26
75.0%
15.3%
Mar '26
Dec '25
Sep '25
HolderSep '25Dec '25Mar '26Jun '26Change
Promoter75.00%75.00%75.00%75.00% 0.00 pts
FII5.00%4.63%4.62%4.79% ▲ +0.17 pts
MF5.00%4.77%4.73%4.87% ▲ +0.14 pts
Other15.00%15.60%15.65%15.34% ▼ −0.31 pts

GlaxoSmithKline Pharmaceuticals Key Metrics

Each ratio placed against a benchmark — the sector average, the company's own 5-year average, or a common rule of thumb.

GlaxoSmithKline PharmaceuticalsBenchmarkRule-of-thumb bands

Valuation The price against earnings, book value and sales

P/E (TTM)Price ÷ yearly earnings per share
44.12
▲ 31% above the sector average of 33.72
P/E, 12-month rangeLow 36.76 · high 74.92
19%
Today's P/E sits 19% of the way from its low to its high
P/BPrice ÷ book value per share
20.80
P/SMarket cap ÷ last 12 months' revenue
11.92
P/CFPrice ÷ cash flow per share
42.03
PEGP/E ÷ earnings growth rate
2.29

Profitability Of every ₹100 of sales, how much is kept?

Gross marginKept after the cost of goods
64.82%
▲ above its 5-yr average of 58.39%
Operating marginKept after running costs
32.53%
▲ above its 5-yr average of 25.38%
Pre-tax marginKept before tax
36.65%
▲ above its 5-yr average of 29.04%
Net marginKept as profit
27.01%
▲ above its 5-yr average of 20.18%

Returns & efficiency How well does it use its money?

Return on equityProfit on shareholders' money
49.11%
▲ above its 5-yr average of 35.40%
Return on assetsProfit on everything it owns
24.57%
▲ above its 5-yr average of 18.31%
Return on investmentProfit on long-term capital
43.64%
▲ above its 5-yr average of 31.28%
Return on capital employedProfit before interest and tax on equity + debt
65.98%

Growth Is the business getting bigger?

Revenue — last 12 months
+5.8%
▲ growing
Revenue — 3 yr, a year
+5.5%
▲ growing
Revenue — 5 yr, a year
+5.5%
▲ growing
Net profit — 3 yr, a year
+19.3%
▲ growing
Net profit — 5 yr, a year
+23.7%
▲ growing
EPS — last 12 months
+12.9%
▲ growing
EPS — 3 yr, a year
+19.5%
▲ growing
EPS — 5 yr, a year
+29.2%
▲ growing (off the scale)
Dividend — 3 yr, a year
+21.2%
▲ growing
Book value — 5 yr, a year
+8.9%
▲ growing

Financial strength Can it pay its bills and debts?

Debt to equityBorrowings for every ₹1 of shareholders' money
0.01×
✓ Low debt
Current ratioShort-term assets for every ₹1 due within a year
2.03×
✓ Comfortable
Quick ratioLike the current ratio, without inventory
1.76×
✓ Comfortable
Interest coverOperating profit ÷ interest to pay
392.02×
✓ Strong
Payout ratioShare of profit paid as dividend
93.21%
• Pays most out

Per share What each share stands for

EPS (TTM)
₹63.05
Book value
₹133.85
Cash flow
₹66.99
Dividend
₹57.00
Revenue
₹233.46

The share price is 20.80× the book value behind each share.

Benchmarks: sector averages and 5-year averages come from the data provider; the debt and liquidity bands are common rules of thumb, not investment advice.

All 110 metrics from the data provider

Valuation

P/E excluding extraordinary items, most recent fiscal year46.04
Current Dividend Yield - Common Stock Primary Issue, LTM2.02
Price to Book - most recent fiscal year21.04
P/E Basic excluding extraordinary items - TTM38.86
P/E including extraordinary items - TTM44.66
P/E excluding extraordinary items low, trailing 12 months36.76
Price to Tangible Book - most fiscal year21.10
Dividend Yield - 5 Year Average1.93
Price to sales - most recent fiscal year12.48
Dividend Yield - indicated annual dividend divided by closing price2.02
Price to Cash Flow per share - trailing 12 month42.03
Peg Ratio2.29
Price to Free Cash Flow per Share - most recent fiscal year355.84
P/E Normalized, most recent fiscal year46.73
P/E excluding extraordinary items high, trailing 12 months74.92
P/E excluding extraordinary items, most recent fiscal year quarter44.66
Price to sales - trailing 12 month12.06
Net Debt, LFY−27,222.03

Per share

Dividend Per Share - 5 year average38.60
Cash Flow per share - trailing 12 month66.99
Cash Flow per share - most recent fiscal year65.07
EPS including extraordinary items - trailing 12 month63.05
EPS including extraordinary items - most recent fiscal year61.15
EBITD per share - trailing 12 month79.89
Revenue/share - trailing 12 month233.46
EPS excluding extraordinary items - trailing 12 month63.05
EPS Basic excluding extraordinary items - most recent fiscal year61.15
EPS Basic excluding extraordinary items - trailing 12 month63.05
Book value per share - most recent fiscal year133.85
Dividend per share - most recent fiscal year57.00
Revenue/share - most recent fiscal year225.59
EPS Normalized - most recent fiscal year60.26
Book value (tangible) per share - most recent fiscal year133.46
Dividends per share - trailing 12 month57.00
EPS excluding extraordinary items - most recent fiscal year61.15
Cash per share - most recent fiscal year162.66

Margins

Operating margin - trailing 12 month32.53
Gross Margin - 5 year average58.39
Operating margin - 1st historical fiscal year32.64
Operating Margin - 5 year average25.38
Net Profit Margin % - 1st historical fiscal year27.11
Gross Margin - 1st historical fiscal year61.84
Net Profit Margin % - trailing 12 month27.01
Net Profit Margin - 5 year average20.18
Pretax Margin - 5 year average29.04
Pretax margin - 1st historical fiscal year36.79
Pretax margin - trailing 12 month36.65
Free Operating Cash Flow/Revenue, 5 Year Average−0.89
Gross Margin - trailing 12 month64.82

Growth

EPS Change %, TTM over TTM12.89
Revenue growth rate, 5 year5.49
EPS growth rate, 5 year29.24
Revenue Change % - most recent quarter 1 year ago16.55
Growth rate% - dividend, 3 year21.22
Growth rate% - EPS, 3 year19.46
Revenue/share (5 yr growth)5.49
Tangible Book Value, Total Equity, 5 Year CAGR9.52
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year Interim CAGR17.02
Capital Spending growth rate, 5 year4.56
Revenue Change %, TTM over TTM5.75
Growth rate% - Revenue, 3 year5.53
Book value per share growth rate, 5 year8.93
EPS Change % - most recent quarter 1 year ago15.70
Net Profit Margin growth rate, 5 year22.52
Earnings Before Interest, Taxes, Depreciation & Amortization, 5 Year CAGR17.04
Total Debt, 5 Year CAGR−0.79

Financial strength

Free Cash Flow - most recent fiscal year1,340.48
LT debt/equity - most recent fiscal year0.01
Quick ratio - most recent fiscal year1.76
Payout ratio - trailing 12 month90.41
Current ratio - most recent fiscal year2.03
Current EV/Free Cash Flow, LFY135.04
Total debt/total equity - most recent fiscal year0.01
Net Interest coverage - trailing 12 month392.02
Payout ratio - most recent fiscal year93.21

Returns & efficiency

Return on average equity - 5 year average35.40
Net Income/employee - trailing 12 month34,42,322.00
Revenue/employee - most recent fiscal year1,22,96,250.00
Return on investment - most recent fiscal year43.64
Return on average assets - most recent fiscal year24.57
Receivables turnover - most recent fiscal year12.99
Inventory turnover - most recent fiscal year3.05
Revenue/employee - trailing 12 month1,27,45,550.00
Return on average assets - 5 year average18.31
Net Income/employee - most recent fiscal year33,33,277.00
Asset turnover - most recent fiscal year0.91
Return on average equity - most recent fiscal year49.11
Return on investment - 5 year average31.28

Price & volume

Market Cap48,991.04
52 week Low Date12 Jun 2026
Price - 1 Day % Change−0.48
Relative (S&P500) price percent change - 13 week24.76
Avg trading volume last 10 days0.06
Price - 13 week price percent change19.57
Price - 52 week price percent change2.83
Avg Trading Volume Last 3 months2.35
Price - 5 Day % Change−0.81
Price % Change Month To Date−7.68
Relative (S&P500) price percent change - 04 week−5.23
52 week High Date28 Aug 2026
Price - 26 week price percent change24.62
PDATE25 Sep 2026
Price - YTD price percent change13.83
Relative (S&P500) price percent change - 52 week12.94
NPRICE2,815.70
Relative (S&P500) price percent change - 26 week24.09
52 week Low2,088.10
52 week High3,120.70
Beta0.56
Relative (S&P500) price percent change - Year to Date31.28

Dividends & Corporate Events

Payouts to shareholders, splits and bonus issues, and company meetings — newest first.

Dividend per share₹ per share, by fiscal year
₹57.00
  • Dividend yield2.05%
  • Payout ratio93.21%
  • 5-year average dividend₹38.60 a share
  • Latest dividend₹57.00 per share · 29 May 2026

Corporate calendar

  • MeetingPostal Ballot
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹57.00 per share · 570% · Final dividend
  • BoardAudited Results & Dividend
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results
Show 14 older events
  • BoardQuarterly Results
  • MeetingAnnual General Meeting
  • Dividend₹42.00 per share · 420% · Final dividend
  • BoardAudited Results & Final Dividend
  • MeetingPostal Ballot
  • BoardQuarterly Results
  • BoardQuarterly Results
  • Dividend₹12.00 per share · 120% · Interim dividend
  • MeetingAnnual General Meeting
  • Dividend₹32.00 per share · 320% · Final dividend
  • Dividend₹32.00 per share · 320% · Final dividend
  • Dividend₹30.00 per share · 300% · Final dividend
  • Dividend₹60.00 per share · 600% · Special special dividend
  • Dividend₹30.00 per share · 300% · Final dividend

About GlaxoSmithKline Pharmaceuticals

Biotechnology & Drugs

GlaxoSmithKline Pharmaceuticals Limited is an India-based global healthcare company. The Company is engaged in the business of manufacturing, distributing and trading in pharmaceuticals. The Company has three product areas: vaccines, specialty and general medicine. Its general medicines business has a portfolio of medicines in anti-infectives, pain, vitamins medicine, nutritional, hormones, dermatologicals, respiratory and vaccines for adults and children. The Company's general medicine brands include Augmentin, Calpol, Ceftum, Eltroxin, CCM, Neosporin, Betnovate, Tenovate, T-bact and Physiogel. The Company's vaccine brands include Shingrix Herpes Zoster Vaccine, Infanrix Hexa, Synflorix, Boostrix, Havrix, Menveo, Fluarix Tetra and Varilrix. Its specialty medicine brands include Nucala, Seretide, and Trelegy Ellipta. Trelegy Ellipta, single inhaler triple therapy (SITT) for chronic obstructive pulmonary disease (COPD) patients. The Subsidiary of the Company is Biddle Sawyer Limited.

Key people

  • Ronojit BiswasChief Financial Officer, Whole-Time Director
  • Carson DaltonExecutive Vice President - Communications and Government Affairs
  • Rishikesh JaiwantExecutive Vice President - Supply Chain Operations
  • Shalini MenonExecutive Vice President - Medical Affairs
  • Amit PandeyExecutive Vice President - Legal
  • Vibhuti GuptaVice President - Commercial Operations and Strategy

Company facts

  • NSE symbolGLAXO
  • BSE code500660
  • ISININE159A01016
  • IndustryBiotechnology & Drugs
  • IndexNIFTY 500
  • Market cap₹47,126 Cr
  • Revenue (FY26)₹3,822 Cr
  • Net profit (FY26)₹1,036 Cr

In the News

Recent headlines about GlaxoSmithKline Pharmaceuticals — they open on Mint in a new tab.

Stock data comes from the exchange feed via our data provider. It is not real-time and can be delayed, so check the price with your broker before you trade. This page is for information and education only. It is not investment advice, research or a recommendation to buy, sell or hold any security. Investments in the securities market are subject to market risks; read all related documents carefully before investing. See all stocks →

Frequently Asked Questions

GlaxoSmithKline Pharmaceuticals (NSE: GLAXO) last traded at ₹2,783.80 on the NSE, down 3.89% (₹112.67) on the day, as of 29 Sep 2026. The day's range on 28 Sep was ₹2,788.80 – ₹2,986.65.

GlaxoSmithKline Pharmaceuticals's 52-week high is ₹3,121.10 (28 Aug 2026) and its 52-week low is ₹2,088.00 (12 Jun 2026). At ₹2,783.80 the share is 10.8% below its high and 33.3% above its low.

GlaxoSmithKline Pharmaceuticals's market capitalisation is ₹47,126 Cr (₹47,126 Cr). It is part of the NIFTY 500 index.

GlaxoSmithKline Pharmaceuticals's P/E ratio (trailing 12 months) is 44.12. The sector average is 33.72, so investors pay 31% more for each rupee of its earnings than for the average company in its sector. Its earnings per share (TTM) are ₹63.05.

GlaxoSmithKline Pharmaceuticals shares are up 4.23% over the last year, up 12.54% so far this year, up 23.20% over 6 months, up 18.24% over 3 months. Over the last year the stock did 12.94% better than the market.

In FY26 (year to Mar 2026), GlaxoSmithKline Pharmaceuticals reported revenue of ₹3,822 Cr (up 1.93% on the year before) and a net profit of ₹1,036 Cr. Earnings per share were ₹61.15.

Yes. GlaxoSmithKline Pharmaceuticals's latest dividend is ₹57.00 per share (570%, final dividend), with an ex-date of 29 May 2026. The dividend yield is 2.05%. It has paid 8 dividends in the records shown on this page.

As of Jun 2026: Promoter 75.00%, FII 4.79%, MF 4.87%, Other 15.34%.

GlaxoSmithKline Pharmaceuticals's listed peers in Biotechnology & Drugs include Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Cipla, Zydus Lifesciences. By market capitalisation it ranks #6 of 6 in this group.

GlaxoSmithKline Pharmaceuticals is almost debt-free — its debt-to-equity ratio is 0.01 and total debt was ₹33 Cr in FY26.